AndrewEugeneHendifarMD
Oncology • Los Angeles, CACancer Genetics/Cancer Risk Assessment, Gastrointestinal Cancer, Hematologic Oncology, Complementary and Integrative
Director, Pancreas Oncology
Dr. Hendifar is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
8700 Beverly Blvd
Suite 1042AC
Los Angeles, CA 90048Phone+1 310-423-2217Fax+1 310-659-3928- Is this information wrong?
Summary
- Dr. Andrew Hendifar is an oncologist in Los Angeles, CA and is affiliated with multiple hospitals in the area, including Keck Hospital of USC, Ronald Reagan UCLA Medical Center, Providence Saint John's Health Center, and Cedars-Sinai Medical Center. He received his medical degree from Tulane University School of Medicine and has been in practice 14 years. He specializes in cancer genetics/cancer risk assessment, gastrointestinal cancer, hematologic oncology, and complementary and integrative and is experienced in pancreatic cancer, amyloidosis, hematologic oncology, neuroendocrine tumors, and myelodysplasia.
Education & Training
University of Southern California/LAC+USC Medical CenterFellowship, Hematology, 2009 - 2010- University of Southern California/LAC+USC Medical CenterFellowship, Medical Oncology, 2007 - 2009
- University of Southern California/LAC+USC Medical CenterResidency, Internal Medicine, 2003 - 2006
Tulane University School of MedicineClass of 2003
Certifications & Licensure
CA State Medical License 2004 - 2026- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies Start of enrollment: 2013 Jun 10
- PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Participants With Stage IV Untreated Pancreatic Cancer Start of enrollment: 2013 May 14
- Veliparib in Combination With Gemcitabine and Intensity Modulated Radiation Therapy in Patients With Pancreatic Cancer Start of enrollment: 2013 Oct 02
- Join now to see all
Publications & Presentations
PubMed
- Patterns of Failure in Patients With Borderline Resectable/Locally Advanced Pancreatic Cancer After Preoperative Chemotherapy and Stereotactic Body Radiation Therapy.Nicholas N Nissen, Alexandra Gangi, Eric M Chung, Diana J Lu, Anthony T Nguyen, Andrew E Hendifar, Jun Gong, Arsen Osipov, Marc A Attiyeh, Katelyn M Atkins, Mitchell K...> ;Advances in Radiation Oncology. 2024 May 1
- Glutamine Supplementation as an Anticancer Strategy: A Potential Therapeutic Alternative to the Convention.Hayato Muranaka, Rasaq Akinsola, Sandrine Billet, Stephen J Pandol, Andrew E Hendifar, Neil A Bhowmick, Jun Gong> ;Cancers. 2024 Mar 5
- The Disproportionate Rise in Pancreatic Cancer in Younger Women Is Due to a Rise in Adenocarcinoma and Not Neuroendocrine Tumors: A Nationwide Time-Trend Analysis Usin...Yi Jiang, Yazan Abboud, Jeff Liang, Brent Larson, Arsen Osipov, Jun Gong, Andrew E Hendifar, Katelyn Atkins, Quin Liu, Nicholas N Nissen, Debiao Li, Stephen J Pandol, ...> ;Cancers. 2024 Feb 28
- Join now to see all
Press Mentions
3 Innovations That Help Detect Killer Cancers EarlierMay 17th, 2023- ABVC Provides Oncology Pipeline UpdatesAugust 22nd, 2022
- Assay Shows Ability to Detect Pancreatic Cancer in People at High RiskFebruary 18th, 2022
- Join now to see all
Professional Memberships
- Member
Hospital Affiliations
Keck Hospital of USCLos Angeles, California
Providence Saint John's Health CenterSanta Monica, California
Cedars-Sinai Medical CenterLos Angeles, California
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
